BioSpace News Archive

Acceleron recognized approximately $11.1 million in royalty revenue for Q2 2020 from approximately $55.0 million in net U.S. sales of REBLOZYL® (luspatercept-aamt) and a $25.0 million regulatory-based milestone from Bristol Myers Squibb

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, reported financial results for the second quarter 2020 and provided an update on operational initiatives.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the second quarter ended June 30, 2020 and provided a general business update.

Profound Medical Corp., the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, reported financial results for the second quarter ended June 30, 2020, and provided an update on its operations.

IRIDEX Corporation reported financial results for the second quarter ended June 27, 2020.

Ziopharm Oncology, Inc., announced its financial results for the second quarter ended June 30, 2020 and provided a corporate update.

Cytokinetics, Incorporated reported financial results for the second quarter of 2020.

Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported financial results for the second quarter of 2020.

Trevi Therapeutics, Inc. announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on August 13, 2020, to provide a corporate update and review the Company’s financial results for the second quarter ended June 30, 2020.

Establishment Labs Holdings Inc., a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, announced it has entered into a definitive agreement with its Italian distributor to transition to a direct sales force in that market, effective August 1, 2020.